tetano
Editor, Senior Moderator
J Cardiol Cases
. 2023 Oct 13;29(1):15-18.
doi: 10.1016/j.jccase.2023.09.006. eCollection 2024 Jan. Recurrent left ventricular thrombus due to essential thrombocythemia complicated by COVID-19
Kenta Matsui[SUP] 1 [/SUP], Tadashi Kitamura[SUP] 1 [/SUP], Shinzo Torii[SUP] 1 [/SUP], Toshiaki Mishima[SUP] 1 [/SUP], Fumiaki Shikata[SUP] 1 [/SUP], Masaomi Fukuzumi[SUP] 1 [/SUP], Shunichiro Fujioka[SUP] 1 [/SUP], Haruna Araki[SUP] 1 [/SUP], Rihito Horikoshi[SUP] 1 [/SUP], Yoshimi Tamura[SUP] 1 [/SUP], Hisaya Mori[SUP] 1 [/SUP], Kagami Miyaji[SUP] 1 [/SUP]
Affiliations
Essential thrombocythemia is a risk factor for thrombosis and hemorrhage. During the perioperative period of cardiac surgery, the risk of thrombosis and hemorrhage increases. Coronavirus disease 2019 (COVID-19) is also associated with thrombosis. We present the case of a 69-year-old man with essential thrombocythemia complicated by COVID-19 who developed a left ventricular thrombus. We performed thrombectomy, but the patient developed recurrent left ventricular thrombus 8 days after surgery. Emergency redo thrombectomy was performed followed by aggressive blood-thinning therapy. The postoperative course was complicated by cardiac tamponade requiring surgical drainage 8 days after the second surgery. The patient was discharged home 25 days after the second operation without any complications.
Learning objective: Left ventricular thrombus is a rare but fatal complication associated with essential thrombocythemia. COVID-19 has also been reported to cause coagulopathy. This case suggested that after surgery for left ventricular thrombus complicated by multiple risk factors including essential thrombocythemia and COVID-19, aggressive blood-thinning therapy with combination of anticoagulation, antiplatelet, and metabolic antagonist may help prevent recurrent thrombosis.
Keywords: COVID-19; Essential thrombocythemia; Left ventricular thrombus.
. 2023 Oct 13;29(1):15-18.
doi: 10.1016/j.jccase.2023.09.006. eCollection 2024 Jan. Recurrent left ventricular thrombus due to essential thrombocythemia complicated by COVID-19
Kenta Matsui[SUP] 1 [/SUP], Tadashi Kitamura[SUP] 1 [/SUP], Shinzo Torii[SUP] 1 [/SUP], Toshiaki Mishima[SUP] 1 [/SUP], Fumiaki Shikata[SUP] 1 [/SUP], Masaomi Fukuzumi[SUP] 1 [/SUP], Shunichiro Fujioka[SUP] 1 [/SUP], Haruna Araki[SUP] 1 [/SUP], Rihito Horikoshi[SUP] 1 [/SUP], Yoshimi Tamura[SUP] 1 [/SUP], Hisaya Mori[SUP] 1 [/SUP], Kagami Miyaji[SUP] 1 [/SUP]
Affiliations
- PMID: 38188321
- PMCID: PMC10770075
- DOI: 10.1016/j.jccase.2023.09.006
Essential thrombocythemia is a risk factor for thrombosis and hemorrhage. During the perioperative period of cardiac surgery, the risk of thrombosis and hemorrhage increases. Coronavirus disease 2019 (COVID-19) is also associated with thrombosis. We present the case of a 69-year-old man with essential thrombocythemia complicated by COVID-19 who developed a left ventricular thrombus. We performed thrombectomy, but the patient developed recurrent left ventricular thrombus 8 days after surgery. Emergency redo thrombectomy was performed followed by aggressive blood-thinning therapy. The postoperative course was complicated by cardiac tamponade requiring surgical drainage 8 days after the second surgery. The patient was discharged home 25 days after the second operation without any complications.
Learning objective: Left ventricular thrombus is a rare but fatal complication associated with essential thrombocythemia. COVID-19 has also been reported to cause coagulopathy. This case suggested that after surgery for left ventricular thrombus complicated by multiple risk factors including essential thrombocythemia and COVID-19, aggressive blood-thinning therapy with combination of anticoagulation, antiplatelet, and metabolic antagonist may help prevent recurrent thrombosis.
Keywords: COVID-19; Essential thrombocythemia; Left ventricular thrombus.
